Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas: Its association with tumor progression and proliferation

Akifumi Hayashi, Shinichi Aishima, Yoshihiro Miyasaka, Kohei Nakata, Katsuya Morimatsu, Yasunori Oda, Eishi Nagai, Yoshinao Oda, Masao Tanaka, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Intraductal papillary mucinous neoplasm is characterized by cystically dilated main and/or branch pancreatic duct with mucus. According to the degree of atypia, intraductal papillary mucinous neoplasm is classified into 3 groups: adenoma, borderline, and carcinoma. Furthermore, intraductal papillary mucinous neoplasm is considered to progress through an adenoma-carcinoma sequence like colorectal carcinoma. Programmed cell death 4 is a recently identified tumor suppressor that was found to inhibit translation. Programmed cell death 4 has been reported to inhibit tumorigenesis, tumor progression, proliferation, invasion, and metastasis in several human malignancies. We examined 108 cases of intraductal papillary mucinous neoplasm by immunohistochemistry and revealed that programmed cell death 4 expression was recognized in both the nucleus and cytoplasm in intraductal papillary mucinous neoplasm. The positive rate of programmed cell death 4 was 79%, 43%, and 10% in adenoma, borderline, and carcinoma, respectively. The positive rate of programmed cell death 4 decreased from adenoma to carcinoma (P < .0001, both adenoma versus borderline and borderline versus carcinoma), indicating that programmed cell death 4 might inhibit tumor progression in intraductal papillary mucinous neoplasm. Programmed cell death 4 expression had a strong relationship with p21 expression (P < .0001) and an inverse correlation with Ki-67 labeling index (r = -0.6255, P < .0001). Thus, programmed cell death 4 might inhibit the proliferation of intraductal papillary mucinous neoplasm; and its inhibition might partly result from cell cycle arrest caused by the up-regulation of p21. In conclusion, programmed cell death 4 may inhibit tumor progression in intraductal papillary mucinous neoplasm; and the loss of programmed cell death 4 expression is representative of the malignant potential of intraductal papillary mucinous neoplasm including the proliferative activity. Therefore, programmed cell death 4 can be an important biomarker for intraductal papillary mucinous neoplasm.

Original languageEnglish
Pages (from-to)1507-1515
Number of pages9
JournalHuman Pathology
Volume41
Issue number11
DOIs
Publication statusPublished - Nov 1 2010

Fingerprint

Pancreatic Neoplasms
Cell Death
Neoplasms
Adenoma
Carcinoma
Pancreatic Ducts
Mucus
Cell Cycle Checkpoints
Colorectal Neoplasms
Carcinogenesis
Cytoplasm
Up-Regulation
Biomarkers
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas : Its association with tumor progression and proliferation. / Hayashi, Akifumi; Aishima, Shinichi; Miyasaka, Yoshihiro; Nakata, Kohei; Morimatsu, Katsuya; Oda, Yasunori; Nagai, Eishi; Oda, Yoshinao; Tanaka, Masao; Tsuneyoshi, Masazumi.

In: Human Pathology, Vol. 41, No. 11, 01.11.2010, p. 1507-1515.

Research output: Contribution to journalArticle

Hayashi, Akifumi ; Aishima, Shinichi ; Miyasaka, Yoshihiro ; Nakata, Kohei ; Morimatsu, Katsuya ; Oda, Yasunori ; Nagai, Eishi ; Oda, Yoshinao ; Tanaka, Masao ; Tsuneyoshi, Masazumi. / Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas : Its association with tumor progression and proliferation. In: Human Pathology. 2010 ; Vol. 41, No. 11. pp. 1507-1515.
@article{e4c2a453e0e84c37802688dec71edf20,
title = "Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas: Its association with tumor progression and proliferation",
abstract = "Intraductal papillary mucinous neoplasm is characterized by cystically dilated main and/or branch pancreatic duct with mucus. According to the degree of atypia, intraductal papillary mucinous neoplasm is classified into 3 groups: adenoma, borderline, and carcinoma. Furthermore, intraductal papillary mucinous neoplasm is considered to progress through an adenoma-carcinoma sequence like colorectal carcinoma. Programmed cell death 4 is a recently identified tumor suppressor that was found to inhibit translation. Programmed cell death 4 has been reported to inhibit tumorigenesis, tumor progression, proliferation, invasion, and metastasis in several human malignancies. We examined 108 cases of intraductal papillary mucinous neoplasm by immunohistochemistry and revealed that programmed cell death 4 expression was recognized in both the nucleus and cytoplasm in intraductal papillary mucinous neoplasm. The positive rate of programmed cell death 4 was 79{\%}, 43{\%}, and 10{\%} in adenoma, borderline, and carcinoma, respectively. The positive rate of programmed cell death 4 decreased from adenoma to carcinoma (P < .0001, both adenoma versus borderline and borderline versus carcinoma), indicating that programmed cell death 4 might inhibit tumor progression in intraductal papillary mucinous neoplasm. Programmed cell death 4 expression had a strong relationship with p21 expression (P < .0001) and an inverse correlation with Ki-67 labeling index (r = -0.6255, P < .0001). Thus, programmed cell death 4 might inhibit the proliferation of intraductal papillary mucinous neoplasm; and its inhibition might partly result from cell cycle arrest caused by the up-regulation of p21. In conclusion, programmed cell death 4 may inhibit tumor progression in intraductal papillary mucinous neoplasm; and the loss of programmed cell death 4 expression is representative of the malignant potential of intraductal papillary mucinous neoplasm including the proliferative activity. Therefore, programmed cell death 4 can be an important biomarker for intraductal papillary mucinous neoplasm.",
author = "Akifumi Hayashi and Shinichi Aishima and Yoshihiro Miyasaka and Kohei Nakata and Katsuya Morimatsu and Yasunori Oda and Eishi Nagai and Yoshinao Oda and Masao Tanaka and Masazumi Tsuneyoshi",
year = "2010",
month = "11",
day = "1",
doi = "10.1016/j.humpath.2010.02.019",
language = "English",
volume = "41",
pages = "1507--1515",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas

T2 - Its association with tumor progression and proliferation

AU - Hayashi, Akifumi

AU - Aishima, Shinichi

AU - Miyasaka, Yoshihiro

AU - Nakata, Kohei

AU - Morimatsu, Katsuya

AU - Oda, Yasunori

AU - Nagai, Eishi

AU - Oda, Yoshinao

AU - Tanaka, Masao

AU - Tsuneyoshi, Masazumi

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Intraductal papillary mucinous neoplasm is characterized by cystically dilated main and/or branch pancreatic duct with mucus. According to the degree of atypia, intraductal papillary mucinous neoplasm is classified into 3 groups: adenoma, borderline, and carcinoma. Furthermore, intraductal papillary mucinous neoplasm is considered to progress through an adenoma-carcinoma sequence like colorectal carcinoma. Programmed cell death 4 is a recently identified tumor suppressor that was found to inhibit translation. Programmed cell death 4 has been reported to inhibit tumorigenesis, tumor progression, proliferation, invasion, and metastasis in several human malignancies. We examined 108 cases of intraductal papillary mucinous neoplasm by immunohistochemistry and revealed that programmed cell death 4 expression was recognized in both the nucleus and cytoplasm in intraductal papillary mucinous neoplasm. The positive rate of programmed cell death 4 was 79%, 43%, and 10% in adenoma, borderline, and carcinoma, respectively. The positive rate of programmed cell death 4 decreased from adenoma to carcinoma (P < .0001, both adenoma versus borderline and borderline versus carcinoma), indicating that programmed cell death 4 might inhibit tumor progression in intraductal papillary mucinous neoplasm. Programmed cell death 4 expression had a strong relationship with p21 expression (P < .0001) and an inverse correlation with Ki-67 labeling index (r = -0.6255, P < .0001). Thus, programmed cell death 4 might inhibit the proliferation of intraductal papillary mucinous neoplasm; and its inhibition might partly result from cell cycle arrest caused by the up-regulation of p21. In conclusion, programmed cell death 4 may inhibit tumor progression in intraductal papillary mucinous neoplasm; and the loss of programmed cell death 4 expression is representative of the malignant potential of intraductal papillary mucinous neoplasm including the proliferative activity. Therefore, programmed cell death 4 can be an important biomarker for intraductal papillary mucinous neoplasm.

AB - Intraductal papillary mucinous neoplasm is characterized by cystically dilated main and/or branch pancreatic duct with mucus. According to the degree of atypia, intraductal papillary mucinous neoplasm is classified into 3 groups: adenoma, borderline, and carcinoma. Furthermore, intraductal papillary mucinous neoplasm is considered to progress through an adenoma-carcinoma sequence like colorectal carcinoma. Programmed cell death 4 is a recently identified tumor suppressor that was found to inhibit translation. Programmed cell death 4 has been reported to inhibit tumorigenesis, tumor progression, proliferation, invasion, and metastasis in several human malignancies. We examined 108 cases of intraductal papillary mucinous neoplasm by immunohistochemistry and revealed that programmed cell death 4 expression was recognized in both the nucleus and cytoplasm in intraductal papillary mucinous neoplasm. The positive rate of programmed cell death 4 was 79%, 43%, and 10% in adenoma, borderline, and carcinoma, respectively. The positive rate of programmed cell death 4 decreased from adenoma to carcinoma (P < .0001, both adenoma versus borderline and borderline versus carcinoma), indicating that programmed cell death 4 might inhibit tumor progression in intraductal papillary mucinous neoplasm. Programmed cell death 4 expression had a strong relationship with p21 expression (P < .0001) and an inverse correlation with Ki-67 labeling index (r = -0.6255, P < .0001). Thus, programmed cell death 4 might inhibit the proliferation of intraductal papillary mucinous neoplasm; and its inhibition might partly result from cell cycle arrest caused by the up-regulation of p21. In conclusion, programmed cell death 4 may inhibit tumor progression in intraductal papillary mucinous neoplasm; and the loss of programmed cell death 4 expression is representative of the malignant potential of intraductal papillary mucinous neoplasm including the proliferative activity. Therefore, programmed cell death 4 can be an important biomarker for intraductal papillary mucinous neoplasm.

UR - http://www.scopus.com/inward/record.url?scp=77957952824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957952824&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2010.02.019

DO - 10.1016/j.humpath.2010.02.019

M3 - Article

C2 - 20656320

AN - SCOPUS:77957952824

VL - 41

SP - 1507

EP - 1515

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 11

ER -